Pinsent Masons advises Teva Pharmaceuticals on €84m sale of its consumer healthcare brand portfolio to Karo Pharma AB.

16 Feb 2021 | 04:00 pm |

Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).

The transaction transfers ownership of the brand portfolio, comprised of Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and Fludent® from Teva to Karo. The transactionis is expected to close on April 1.

The Pinsent Masons team was jointly led by partners Allistair Booth and Thilo Schneider and included senior associate Ciaran Wilkinson.

Commenting on the transaction Thilo Schneider said:

"I am so pleased that we have been able to support Teva and to have brought this transaction to a successful conclusion. The sale is significant for both parties and we are proud to have achieved a successful outcome for Teva. We worked closely with them to understand what they wanted to achieve and helped to determine the best options available to them." 

Latest press releases

Show me all press releases

Pinsent Masons launches paralegal focused trainee programme partnership with LexisNexis

Multinational law firm Pinsent Masons has launched a paralegal Solicitor Qualifying Examination (SQE) career pathway initiative with LexisNexis as it seeks to broaden access to the legal profession.

Pinsent Masons advises Ocean Winds on exclusive offshore wind joint venture with Bord na Móna

Multinational law firm Pinsent Masons has advised leading global offshore wind energy developer Ocean Winds on a partnership with Ireland’s climate solutions company Bord na Móna to develop projects that will generate up to 2.3GW of clean and renewable electricity to power up to 2.1million homes by 2030.

Pinsent Masons wins three awards at the British Legal Awards 2022

Multinational law firm Pinsent Masons won M&A Team of the Year (medium deal), TMT Team of the Year and Litigation & Dispute Resolution Team of the Year at the British Legal Awards 2022.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises Cathexis on acquisition of Jones Engineering

Multinational law firm Pinsent Masons has advised Cathexis Holdings, LP on the acquisition of Jones Engineering Holdings International Limited.

Pinsent Masons advises UMS Consulting on its acquisition by Expleo

Multinational law firm Pinsent Masons has advised the shareholders of UMS Consulting GmbH & Co. KG on the sale of their shares to Expleo Group S.A.S.

Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe

Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.